Siponimod and Cognition in Secondary Progressive Multiple Sclerosis EXPAND Secondary Analyses

被引:55
作者
Benedict, Ralph H. B. [1 ]
Tomic, Davorka [2 ]
Cree, Bruce A. [3 ]
Fox, Robert [4 ]
Giovannoni, Gavin [5 ]
Bar-Or, Amit [6 ]
Gold, Ralf [7 ]
Vermersch, Patrick [8 ]
Pohlmann, Harald [2 ]
Wright, Ian [9 ]
Karlsson, Goril [2 ,11 ,12 ,13 ,14 ,15 ]
Dahlke, Frank [2 ]
Wolf, Christian [10 ]
Kappos, Ludwig [11 ,12 ,13 ,14 ,15 ]
机构
[1] Univ Buffalo, Dept Neurol, Buffalo, NY 14260 USA
[2] Novartis Pharma AG, Basel, Switzerland
[3] Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA USA
[4] Cleveland Clin, Neurol Inst, Mellen Ctr Treatment & Res Multiple Sclerosis, Cleveland, OH USA
[5] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England
[6] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA
[7] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany
[8] Univ Lille, INSERM U1172, CHU Lille, FHU Imminent,Dept Neurol, Lille, France
[9] Novartis Ireland Ltd, Dublin, Ireland
[10] Lycalis sprl, Brussels, Belgium
[11] Univ Hosp, Dept Med, Basel, Switzerland
[12] Univ Hosp, Dept Clin Res, Basel, Switzerland
[13] Univ Hosp, Dept Biomed, Basel, Switzerland
[14] Univ Hosp, Dept Biomed Engn, Basel, Switzerland
[15] Univ Basel, Basel, Switzerland
关键词
INFORMATION-PROCESSING SPEED; DIGIT MODALITIES TEST; INTERFERON BETA-1A; PERFORMANCE; RELIABILITY; PASAT; THALAMUS; ATROPHY; DEFICIT; TRIALS;
D O I
10.1212/WNL.0000000000011275
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To investigate the effects of siponimod on cognitive processing speed in patients with secondary progressive (SP) multiple sclerosis (MS), bymeans of a predefined exploratory and post hoc analysis of the Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) study, a randomized controlled trial comparing siponimod and placebo. Methods EXPAND was a double-blind, placebo-controlled phase 3 trial involving 1,651 patients with SPMS randomized (2:1) to either siponimod 2 mg/d or placebo. Cognitive function was assessed with the Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test (PASAT), and Brief Visuospatial Memory Test-Revised (BVMT-R) administered at baseline, 6-month intervals, and end of treatment. Results Between-group differences in mean change from baseline in SDMT scores were significantly better in siponimod- vs placebo-treated patients at month 12 (difference 1.08 [95% confidence interval 0.23-1.94]; p = 0.0132), month 18 (1.23 [0.25-2.21); p = 0.0135), and month 24 (2.30 [1.11-3.50]; p = 0.0002). Siponimod-treated patients were at significantly lower risk for having a 4-point sustained decrease in SDMT score (hazard ratio [HR] 0.79 [0.65-0.96]; p = 0.0157), while their chance for having a 4-point sustained increase in SDMT score was higher (HR 1.28 [1.05-1.55]; p = 0.0131). PASAT and BVMT-R scores did not differ significantly between the 2 treatment groups (all p > 0.28). Conclusion Siponimod had a significant benefit on SDMT in patients with SPMS. Siponimod-treated patients were at significantly lower risk for having a >= 4-point decrease in SDMT score and had a significantly higher chance for having a >= 04-point increase in SDMT score, a magnitude of change accepted as clinically meaningful. Classification of Evidence This study provides Class II evidence that, for patients with SPMS, siponimod had a significant benefit on cognitive processing speed.
引用
收藏
页码:E376 / E386
页数:11
相关论文
共 61 条
  • [1] Arnold DA, 2019, 35 C EUR COMM TREATM, P382
  • [2] Aslanis V, 2012, MULT SCLER J, V18, P355
  • [3] Within session practice effects on the PASAT in clients with multiple sclerosis
    Barker-Collo, SL
    [J]. ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2005, 20 (02) : 145 - 152
  • [4] Benedict R.H. B., 2012, NINDS common data elements, multiple sclerosis, neuropsychology/cognition recommendations
  • [5] Neuropsychology of Multiple Sclerosis: Looking Back and Moving Forward
    Benedict, Ralph H. B.
    DeLuca, John
    Enzinger, Christian
    Geurts, Jeroen J. G.
    Krupp, Lauren B.
    Rao, Stephen M.
    [J]. JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2017, 23 (9-10) : 832 - 842
  • [6] Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
    Benedict, Ralph H. B.
    Cohan, Stanley
    Lynch, Sharon G.
    Riester, Katherine
    Wang, Ping
    Castro-Borrero, Wanda
    Elkins, Jacob
    Sabatella, Guido
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (06) : 795 - 804
  • [7] Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
    Benedict, Ralph H. B.
    DeLuca, John
    Phillips, Glenn
    LaRocca, Nicholas
    Hudson, Lynn D.
    Rudick, Richard
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (05) : 721 - 733
  • [8] Characterizing cognitive function during relapse in multiple sclerosis
    Benedict, Ralph H. B.
    Morrow, Sarah
    Rodgers, Jonathan
    Hojnacki, David
    Bucello, Margaret A.
    Zivadinov, Robert
    Weinstock-Guttman, Bianca
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (13) : 1745 - 1752
  • [9] Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: implications for multiple sclerosis clinical trials
    Benedict, Ralph H. B.
    Smerbeck, Audrey
    Parikh, Rajavi
    Rodgers, Jonathan
    Cadavid, Diego
    Erlanger, David
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (09) : 1320 - 1325
  • [10] Revision of the brief visuospatial memory test: Studies of normal performance, reliability, and validity
    Benedict, RHB
    Schretlen, D
    Groninger, L
    Dobraski, M
    Shpritz, B
    [J]. PSYCHOLOGICAL ASSESSMENT, 1996, 8 (02) : 145 - 153